CSPC Pharmaceutical Group (HKG:1093) reported an over 139% jump in attributable profit for the first half of 2026 to 6.09 billion yuan from 2.55 billion yuan a year earlier, according to a Thursday Hong Kong bourse filing.
Earnings per share for the six months ended June 30 climbed to 0.5336 yuan from 0.2229 yuan in the prior-year period.
Revenue of the pharma company jumped 40.1% year on year to 18.6 billion yuan from 13.3 billion yuan.
The company declared an interim dividend of HK$0.18 per share, payable on Nov. 10 to shareholders of record on Oct. 26.
Shares of the company jumped nearly 14% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments